PTCT insider Form 4 shows stock option exercises and sales

Rhea-AI Filing Summary

PTC Therapeutics (PTCT) director reports option exercises and stock sales. A board member exercised stock options on 11/24/2025 and 11/25/2025 at exercise prices of $11.23 and $18.01 per share, converting options into common stock. On the same dates, the director sold shares in multiple transactions at weighted average prices generally between the low $80 and mid $80 per share. After these transactions, the director directly owned 17,451 shares of PTC Therapeutics common stock. The filing states that the trades were carried out under a written Rule 10b5-1 trading plan adopted on March 12, 2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jacobson Allan Steven

(Last) (First) (Middle)

C/O PTC THERAPEUTICS, INC.

500 WARREN CORPORATE CENTER DRIVE

(Street)

WARREN NJ 07059

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/24/2025		M(1)		5,701	A	$11.23	23,152	D
Common Stock	11/24/2025		S(1)		5,701	D	$80.13(2)	17,451	D
Common Stock	11/24/2025		M(1)		6,100	A	$18.01	23,551	D
Common Stock	11/24/2025		S(1)		6,100	D	$80.15(2)	17,451	D
Common Stock	11/25/2025		M(1)		6,299	A	$11.23	23,750	D
Common Stock	11/25/2025		S(1)		2,264	D	$82.63(3)	21,486	D
Common Stock	11/25/2025		S(1)		2,510	D	$83.93(4)	18,976	D
Common Stock	11/25/2025		S(1)		1,125	D	$84.45(5)	17,851	D
Common Stock	11/25/2025		S(1)		400	D	$85.24(6)	17,451	D
Common Stock	11/25/2025		M(1)		7,900	A	$18.01	25,351	D
Common Stock	11/25/2025		S(1)		2,460	D	$82.58(3)	22,891	D
Common Stock	11/25/2025		S(1)		3,502	D	$83.38(4)	19,389	D
Common Stock	11/25/2025		S(1)		1,238	D	$84.47(7)	18,151	D
Common Stock	11/25/2025		S(1)		700	D	$85.32(8)	17,451	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$11.23	11/24/2025		M(1)			5,701	(9)	01/02/2027	Common Stock	5,701	$0	6,299	D
Stock Option (Right to Buy)	$18.01	11/24/2025		M(1)			6,100	(9)	01/02/2028	Common Stock	6,100	$0	7,900	D
Stock Option (Right to Buy)	$11.23	11/25/2025		M(1)			6,299	(9)	01/02/2027	Common Stock	6,299	$0	0	D
Stock Option (Right to Buy)	$18.01	11/25/2025		M(1)			7,900	(9)	01/02/2028	Common Stock	7,900	$0	0	D

Explanation of Responses:

1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 12, 2025

2. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $80.00 to $80.72 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

3. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $82.00 to $82.98 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

4. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $83.00 to $83.97 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

5. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $84.00 to $84.81 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

6. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $85.14 to $85.34 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

7. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $84.00 to $84.97 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

8. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $85.00 to $85.60 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

9. Currently exercisable.

	/s/ Avraham S. Adler, Attorney-in-Fact	11/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the PTC Therapeutics (PTCT) Form 4 filing report?

The Form 4 reports that a director of PTC Therapeutics exercised stock options on 11/24/2025 and 11/25/2025 and sold shares of common stock on those same dates.

How many PTC Therapeutics shares does the director own after these transactions?

Following the reported option exercises and sales, the director beneficially owned 17,451 shares of PTC Therapeutics common stock in direct ownership.

At what prices were the PTC Therapeutics stock options exercised in this Form 4?

The director exercised stock options with exercise prices of $11.23 and $18.01 per share, converting options into PTC Therapeutics common stock.

At what prices were PTC Therapeutics (PTCT) shares sold in the Form 4 transactions?

The reported sales were executed at weighted average prices, including $80.13, $82.63, $83.93, $84.45, $85.24, $82.58, $83.38, $84.47, and $85.32 per share, each reflecting trades within specified price ranges.

Were the PTC Therapeutics director’s trades made under a Rule 10b5-1 trading plan?

Yes. The filing states that the transactions were effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 12, 2025.

What types of securities are reported in this PTC Therapeutics Form 4?

The Form 4 reports transactions in common stock and in stock options (rights to buy) that were exercised into common shares.

What is the director’s role and filing status in relation to PTC Therapeutics (PTCT)?

The reporting person is identified as a director of PTC Therapeutics, and the Form 4 is filed by one reporting person, indicating an individual filing.